The Non-Malignant Channel is supported with funding from Agios (Gold).
The Thalassemia Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Phase IIa study of vamifeport in patients with non-transfusion-dependent beta-thalassemia
Ali Taher, MD, PhD, American University of Beirut Medical Center, Beirut, Lebanon, outlines the mechanism of action of vamifeport and comments on the results of a Phase IIa study evaluating the safety, tolerability, and preliminary efficacy of vamifeport in patients with non-transfusion-dependent beta-thalassemia (NTDT; NCT04364269). The study achieved its primary and secondary endpoints, reporting a favorable tolerability profile and promising target engagement on serum iron and transferrin saturation levels versus placebo in this patient population. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Novartis Pharmaceuticals: Consultancy, Research funding; Bristol-Myers Squibb (Celgene): Consultancy, Research funding; Ionis Pharmaceuticals: Consultancy, Research Funding; Vifor: Consultancy, Research Funding; Imara: Consultancy, Research Funding; Agios: Consultancy
